MARKET

NURPF

NURPF

Neuren Pharma
OTCPK
14.00
NaN%
Closed 09:30 11/20 EST
OPEN
--
PREV CLOSE
14.00
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
17.08
52 WEEK LOW
7.75
MARKET CAP
1.77B
P/E (TTM)
131.09
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF) and Ramsay Health Care (OtherRMSYF)
TipRanks · 2d ago
Neuren Files Final Director’s Interest Notice for Patrick Davies
TipRanks · 11/12 11:12
Neuren Appoints Zita Peach as Board Chair
TipRanks · 11/12 11:04
Macquarie Sticks to Their Buy Rating for Neuren Pharmaceuticals Limited (NURPF)
TipRanks · 11/06 05:05
*Neuren Pharmaceuticals Price Target Raised 6% to A$26.00/Share by Macquarie
Dow Jones · 11/06 01:28
Ord Minnett Sticks to Its Buy Rating for Neuren Pharmaceuticals Limited (NURPF)
TipRanks · 11/06 00:46
Analysts’ Top Healthcare Picks: Neuren Pharmaceuticals Limited (NURPF), Sight Sciences (SGHT)
TipRanks · 11/06 00:10
*Neuren Pharmaceuticals Price Target Raised 4.8% to A$34.88/Share by Petra Capital
Dow Jones · 11/05 23:23
More
About NURPF
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is developing new drug therapies to treat multiple serious neurological disorders that are caused by genetic abnormalities or brain injury and have no or limited approved treatment options. Its product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. Its other product, NNZ-2591, is an investigational medicine in Phase III clinical trial for Phelan-McDermid syndrome. Its NNZ-2591 other programs include Pitt Hopkins syndrome, Angelman syndrome, Prader-Willi Syndrome and SYNGAP1-related disorder. The United States Food and Drug Administration (FDA) and European Medicines Agency have both granted Orphan drug designation for trofinetide in Rett syndrome and Fragile X syndrome and for NNZ-2591. The Company has granted a worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.

Webull offers Neuren Pharmaceuticals Ltd stock information, including OTCPK: NURPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURPF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NURPF stock methods without spending real money on the virtual paper trading platform.